Stock TLPH TALPHERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Talphera, Inc.

Equities

TLPH

US00444T2096

Delayed Nasdaq
Other stock markets
 10:00:18 2024-05-22 am EDT 		5-day change 1st Jan Change
1.03 USD -1.90% Intraday chart for Talphera, Inc. -15.23% +40.14%
May. 14 Transcript : Talphera, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14 Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
Talphera to Participate at A.G.P. Virtual Healthcare Conference
PR
Talphera: Q1 Earnings Snapshot
AQ
Talphera: Q4 Earnings Snapshot
AQ
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
AQ
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
PR
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition
AQ
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
PR
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
PR
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
PR
AcelRx Pharmaceuticals: Q3 Earnings Snapshot
AQ
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PR
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
PR
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
PR
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
PR
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
PR
AcelRx Pharmaceuticals: Q2 Earnings Snapshot
AQ
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
PR
AcelRx Pharmaceuticals : Management’s Discussion and Analysis of Financial Condition and Results of Operations - Form 8-K
PU
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TLPH Stock
  4. News Talphera, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW